Evidence map›Paper›PMID 20811039›Full record

ArticleDiabetes2011

Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure.

Michal M Poplawski, Jason W Mastaitis, Charles V Mobbs

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Regulation of peripheral metabolism by substrate partitioning in the brain.Endocrinology and metabolism clinics of North America · 2013
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michal M PoplawskiFishberg Center for Neurobiology, Mount Sinai School of Medicine, New York, New York, USA.
Jason W Mastaitis
Charles V Mobbs
Icahn School of Medicine at Mount Sinai · US

Funding

Stable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI FLEISCHER, NORMAN S. · 1986 to 2014
$29.8M
6 · The paper itself

Abstract

objectiveHypoglycemia-associated autonomic failure (HAAF) constitutes one of the main clinical obstacles to optimum treatment of type 1 diabetes. Neurons in the ventromedial hypothalamus are thought to mediate counterregulatory responses to hypoglycemia. We have previously hypothesized that hypoglycemia-induced hypothalamic angiotensin might contribute to HAAF, suggesting that the angiotensin blocker valsartan might prevent HAAF. On the other hand, clinical studies have demonstrated that the opioid receptor blocker naloxone ameliorates HAAF. The goal of this study was to generate novel hypothalamic markers of hypoglycemia and use them to assess mechanisms mediating HAAF and its reversal. RESEARCH DESIGN AND

methodsQuantitative PCR was used to validate a novel panel of hypothalamic genes regulated by hypoglycemia. Mice were exposed to one or five episodes of insulin-induced hypoglycemia, with or without concurrent exposure to valsartan or naloxone. Corticosterone, glucagon, epinephrine, and hypothalamic gene expression were assessed after the final episode of hypoglycemia.

resultsA subset of hypothalamic genes regulated acutely by hypoglycemia failed to respond after repetitive hypoglycemia. Responsiveness of a subset of these genes was preserved by naloxone but not valsartan. Notably, hypothalamic expression of four genes, including pyruvate dehydrogenase kinase 4 and glycerol 3-phosphate dehydrogenase 1, was acutely induced by a single episode of hypoglycemia, but not after antecedent hypoglycemia; naloxone treatment prevented this failure. Similarly, carnitine palmitoyltransferase-1 was inhibited after repetitive hypoglycemia, and this inhibition was prevented by naloxone. Repetitive hypoglycemia also caused a loss of hypoglycemia-induced elevation of glucocorticoid secretion, a failure prevented by naloxone but not valsartan.

conclusionsBased on these observations we speculate that acute hypoglycemia induces reprogramming of hypothalamic metabolism away from glycolysis toward β-oxidation, HAAF is associated with a reversal of this reprogramming, and naloxone preserves some responses to hypoglycemia by preventing this reversal.

Indexed as

Angiopoietin-Like Protein 4AngiopoietinsAnimalsAntihypertensive AgentsApoptosis Regulatory ProteinsBlood GlucoseCarrier ProteinsCyclin-Dependent Kinase Inhibitor p21Glucose Transporter Type 2Glycerolphosphate DehydrogenaseHomeostasisHypoglycemiaInsulinMembrane ProteinsMiceNaloxoneAngiopoietin-Like Protein 4AngiopoietinsAngptl4 protein, mouseAntihypertensive AgentsApoptosis Regulatory ProteinsBlood GlucoseCarrier ProteinsCdkn1a protein, mouseCyclin-Dependent Kinase Inhibitor p21Glucose Transporter Type 2Glycerolphosphate DehydrogenaseHif3a protein, mouseInsulinMembrane ProteinsNaloxoneNarcotic AntagonistsPerilipin-4Plin4 protein, mouseProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseRepressor ProteinsSlc2a2 protein, mouseTetrazolesTranscription FactorsValineValsartan

Identifiers

PMID20811039
PMCPMC3012195
OpenAlexW2130634848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.